Vitamin D3 deficient ACO patients with placebo at day 0.

Vitamin D3 deficient ACO patients with placebo at day 90.

Vitamin D3 deficient ACO patients with vitamin D3 at day 0.

Vitamin D3 deficient ACO patients with vitamin D3 at day 90.

Asthma-COPD Overlap Syndrome

Vitamin D Deficiency

Cardiac Autonomic Tone

The intervention was given by oral administration of vitamin D3 capsule each of which contains 40000 IU of vitamin D3. The capsule was manufactured and supplied by Beximco Pharmaceutical Limited, Bangladesh. The placebo was also be manufactured and supplied by the same pharmaceutical company and was similar in size shape & appearance to vitamin D3 capsule but contained all the ingredients of vitamin D capsule other than the vitamin D3

Vitamin D capsule

placebo

Dr Sultana Ferdousi

Impact of Vitamin D3 Administration on Cardiac Autonomic Tone in Asthma Chronic Obstructive Pulmonary Disease(COPD) Overlap Patients

Impact of Vitamin D3 Administration on Cardiac Autonomic Tone in Asthma COPD Overlap(ACO) Patients: A Blinded Randomized Control Trial

serum vitamin D level was measured at day 0 and after 90 days of vitamin D and placebo administration in vitamin D and in placebo group respectively

Mean R-R interval was measured at day 0 and after 90 days of vitamin D and placebo administration in vitamin D and in placebo group respectively

Mean Heart Rate was measured at day 0 and after 90 days of vitamin D and placebo administration in vitamin D and in placebo group respectively

Standard deviation of RR interval (SDRR) was measured at day 0 and after 90 days of vitamin D and placebo administration in vitamin D and in placebo group respectively

Coefficient of variation of all the R-R interval (CVRR) was measured at day 0 and after 90 days of vitamin D and placebo administration in vitamin D and in placebo group respectively

Square root of the mean squared differences of successive RR interval (RMSSD) was measured at day 0 and after 90 days of vitamin D and placebo administration in vitamin D and in placebo group respectively

Standard deviation of successive RR interval differences between adjacent RR intervals (SDSD) was measured at day 0 and after 90 days of vitamin D and placebo administration in vitamin D and in placebo group respectively

Number of RR interval differing by >50 milliseconds from adjacent intervals divided by the total number of all RR intervals (pRR50%) was measured at day 0 and after 90 days of vitamin D and placebo administration in vitamin D and in placebo group respectively

Total power (absolute) in frequency domain parameters of heart rate variability was measured at day 0 and after 90 days of vitamin D and placebo administration in vitamin D and in placebo group respectively

Low Frequency (LF) power (absolute) in frequency domain parameters of heart rate variability was measured at day 0 and after 90 days of vitamin D and placebo administration in vitamin D and in placebo group respectively

High Frequency (HF) power (absolute) in frequency domain parameters of heart rate variability was measured at day 0 and after 90 days of vitamin D and placebo administration in vitamin D and in placebo group respectively

Low Frequency (LF) power in normalised units (n.u) in frequency domain parameters of heart rate variability was measured at day 0 and after 90 days of vitamin D and placebo administration in vitamin D and in placebo group respectively

High Frequency (HF) power in normalised units (n.u) in frequency domain parameters of heart rate variability was measured at day 0 and after 90 days of vitamin D and placebo administration in vitamin D and in placebo group respectively

Ratio of Low frequency to High Frequency (HF) power in frequency domain parameters of heart rate variability was measured at day 0 and after 90 days of vitamin D and placebo administration in vitamin D and in placebo group respectively

Salsa Bil Nahar

Resident

Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Baseline group:
This group will include 60 vitamin D3 deficient ACO patients.
Group A:
Group A0: Vitamin D3 deficient ACO patients with placebo at day 0. Group A90: Vitamin D3 deficient ACO patients with placebo at day 90
Group B:
Group B0: Vitamin D3 deficient ACO patients with vitamin D3 at day 0. Group B90: Vitamin D3 deficient ACO patients with vitamin D3 at day 90.
All the patients will be similar by age, sex and BMI

Both the patients and the principal investigator will remain blind to the intervention given. After the end of follow up, at the time of data analysis principal investigator will be provided with the information about which patient isgoven placebo and which patient isgivev drug.

Subjects would introduce 5 different groups of FODMAPs in a blinded fashion (random order, 1 week on, one week off) while remaining on an otherwise low FODMAP diet while monitoring their IBS symptoms.

Irritable Bowel Syndrome

After 2 weeks on a low FODMAP diet, subject will undergo a reintroduction period. 5 different FODMAPs will be reintroduced (1 week at a time, followed by 1 week washout) in a blinded, randomized fashion.

FODMAP

University of Michigan

Diet Reintroduction Study in Irritable Bowel Syndrome

Charting a Course to a Less Restrictive Diet for IBS

Daily score (0-10) for abdominal pain will be recorded. This will be averaged and compared to the baseline and run-in periods

Daily score (0-10) for bloating will be recorded. This will be averaged and compared to the baseline and run-in periods

Daily stool consistency score will be recorded. This will be averaged and compared to the baseline and run-in periods

Daily number of stools will be recorded. This will be averaged and compared to the baseline and run-in periods

Daily score (0-10) for stool urgency will be recorded. This will be averaged and compared to the baseline and run-in periods

Daily score (0-10) for fatigue will be recorded. This will be averaged and compared to the baseline and run-in periods

Daily score (0-10) for sleep quality will be recorded. This will be averaged and compared to the baseline and run-in periods

Shanti Eswaran

Clinical Assistant Professor

Food items will be blindly reintroduced, and symptoms will be measured.

Participants blinded to randomization of order of reintroduction; Investigators blinded to order of reintroduction

Sucrose 50 g + D-allulose (psicose) 2.5 g

Sucrose 50 g + D-allulose (psicose) 7.5 g

Impaired Glucose Tolerance

Eligible subjects will come for visit 1 to consume varying dose of D-allulose with sucrose beverage with 1 of 5 beverages in a random order which will be blinded for both subjects and investigators. They will have to do 24-hour dietary record a day prior to each visit. Subjects have to be abstained from energy diet within 8 hours prior to each visit. Venous blood samples will be collected 6 mL for measurement of FPG and insulin before taking any study product. Subjects have to drink all within 1 minute. Blood samples will be drawn again 6 mL at 30, 60, 90 and 120 min after consumption for measurement of PG and insulin. Every subject will be asked to come back to finish OSTT with 5 study products in a random order, each at 7 days or >5 days and <12 days apart.

D-allulose

Clinical trial Unit, Faculty of Medicine, Chiang Mai University

Effects of D-allulose (Psicose) With Sucrose Beverage on Glucose Tolerance and Insulin Level

The Dose-response Effects of D-allulose (Psicose) With Sucrose Beverage on Glucose Tolerance and Insulin Level in Healthy Volunteers and Volunteers With Impaired Fasting Glucose

oral sucrose tolerance test with sucrose +/- allulose

Oral sucrose tolerance test with sucrose +/- allulose

Supawan Buranapin

Assisstant Professor Supawan Buranapin, MD

Chiang Mai University

Kagawa University

Individual has one or more known CSID mutations.

Individual does not have any known CSID mutations.

CSID Mutations

Control

Total

Sex: Female, Male

Region of Enrollment

Prevalence of CSID genetic variants in subjects 18 years of age or younger with a primary symptom of chronic idiopathic diarrhea or chronic abdominal pain without constipation.

Prevalence of CSID Genetic Variants

Overall Study

Heather Smith, Director of One Patient Services

Congenital Sucrase-isomaltase Deficiency (CSID)

Children's Hospital Los Angeles

Children's Hospital and Research Center of Oakland

Children's Hospital of Colorado

Arnold Palmer Children's Hospital

Children's Center for Digestive Healthcare

Ann & Robert H. Lurie Children's Hospital of Chicago

Riley Hospital for Children

Johns Hopkins Children's Center

Massachusetts General Hospital

University of Mississippi Medical Center

Children's Mercy Hospital

Morgan Stanley Children's Hospital

Stony Brook University

Duke University Children's Hospital

Nationwide Children's Hospital

Children's Hospital of Philadelphia

Texas Children's Hospital

Primary Children's Medical Center

Children's Hospital of Wisconsin

Congenital Sucrase-Isomaltase Deficiency (CSID) Genetic Prevalence Study (GPS)

A Multi-Center Study of the Prevalence of Known Congenital Sucrase-Isomaltase Deficiency (CSID) Genetic Variants and Functional Sucrase Activity by 13C-Sucrose Breath Test in Children With Chronic Diarrhea or Chronic Abdominal Pain

sucrose/niðurgangur

Impact of Vitamin D3 Administration on Cardiac Autonomic Tone in Asthma Chronic Obstructive Pulmonary Disease(COPD) Overlap Patients

Diet Reintroduction Study in Irritable Bowel Syndrome

Effects of D-allulose (Psicose) With Sucrose Beverage on Glucose Tolerance and Insulin Level

Congenital Sucrase-Isomaltase Deficiency (CSID) Genetic Prevalence Study (GPS)

Heillasta gagnagrunnur lækningajurtanna sem studdur er af vísindum